阿替普酶溶栓治疗心源性脑栓塞的临床效果观察

Observation on the clinical effect and safety of alteplase thrombolysis for cardiogenic cerebral embolism,GCS score and vascular recanalization rate

目的:观察阿替普酶溶栓治疗心源性脑栓塞的临床效果。方法:2017年7月-2018年8月收治心源性脑栓塞患者50例,分为两组,各25例。对照组给予低分子肝素钠治疗,观察组给予阿替普酶溶栓治疗。比较两组治疗效果。结果:观察组临床治疗效果、血管再通率及GCS评分均显著优于对照组,差异有统计学意义(P<0.05)。两组患者用药安全性均较高,差异无统计学意义(P>0.05)。结论:针对心源性脑栓塞患者采用阿替普酶溶栓治疗,其安全性较高,可有效提高临床治疗效果及血管再通率,改善患者意识障碍。

Objective:To observe the he clinical effect and safety of alteplase thrombolysis for cardiogenic cerebral embolism,GCS score and vascular recanalization rate.Methods:50 patients with cardiogenic cerebral embolism were selected from July 2017 to August 2018,they were divided into the two groups with 25 cases in each group.The control group was treated with low molecular weight heparin sodium and the observation group was treated with ateplase thrombolysis.We compared the therapeutic effect of the two groups.Results:The clinical therapeutic effect,recanalization rate and GCS score of the observation group were significantly better than those of the control group,the differences were statistically significant(P<0.05).The safety of medication was higher in the two groups,and the difference was not statistically significant(P>0.05).Conclusion:Alteplase thrombolytic therapy for patients with cardiogenic cerebral embolism has higher safety,which can effectively improve the clinical treatment effect and vascular recanalization rate,and improve the conscious disturbance of patients.